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White adipose tissue regulates metabolism; the
importance of this control is highlighted by the
ongoing pandemic of obesity and associated com-
plications such as diabetes, atherosclerosis, and
cancer. White adipose tissue maintenance is a
dynamic process, yet very little is known about how
pharmacologic stimuli affect such plasticity. Com-
bining in vivo lineage marking and BrdU labeling
strategies, we found that rosiglitazone, a member of
the thiazolidinedioneclassofglucose-loweringmedi-
cines, markedly increases the evolution of adipose
progenitors into adipocytes. Notably, chronic rosigli-
tazone administration disrupts the adipogenic and
self-renewal capacities of the stem cell compartment
and alters its molecular characteristics. These data
unravel unknown aspects of adipose dynamics and
provide a basis to manipulate the adipose lineage
for therapeutic ends.
INTRODUCTION
Adipose tissue is a central component of metabolic control
(Spiegelman and Flier, 2001). A surfeit or a deficiency of adipose
tissue compromises its ability to maintain metabolic homeo-
stasis. Indeed, the current epidemic of obesity is accompanied
by a proportionate increase in a multitude of untoward sequelae;
notable among them are diabetes, hyperlipidemia, hypertension,
cardiovascular disease, and cancer (Kopelman, 2000). Thus,
appropriate homeostatic balance of the adipocyte pool (i.e.,
number, mass, formation, replacement) is essential for health.
Evolving evidence, including human retrospective analyses in
the wake of atmospheric radioisotope discharges, indicates that
adipocytes constantly turn over and are replenished (Spalding
et al., 2008). External stimuli, such as calorie excess, appear
able to influence this flow, possibly stimulating stem cell behav-
iors (Faust et al., 1978; Joe et al., 2009). Some evidence indi-
cates that the thiazolidinedione (TZD) family of antidiabetes
drugs remodel adipose tissue (de Souza et al., 2001). TZDs are
potent adipogenic factors in vitro (Hiragun et al., 1988; Sandouk
et al., 1993). In vivo, these molecules reduce blood sugar, but
their administration is often accompanied by the unpleasant
side effect of weight gain (Yki-Ja¨rvinen, 2004). This may in part116 Cell Metabolism 14, 116–122, July 6, 2011 ª2011 Elsevier Inc.be explained by histological studies indicating that TZDs
induce recruitment of new adipocytes; it is postulated that this
mobilization is a component of the beneficial effects of TZDs
(Hallakou et al., 1997; de Souza et al., 2001; Fonseca, 2003).
Therefore, TZDs may provide a powerful tool to unravel mecha-
nisms underlying adipose tissue plasticity. Defining whether
and how these molecules act on stem cells may provide an
impetus to further exploit control of adipose progenitor activity
as a therapeutic strategy for obesity and diabetes.
Through inducible genetic marking, lineage tracing, and flow
methodologies, termed AdipoTrak, we recently identified
progenitors that are central to adipose development (Tang
et al., 2008). Friedman, Rossi, and their respective colleagues,
by means of flow cytometry-based approaches, also identified
adipose stem cells that have many similar characteristics to
those we identified with AdipoTrak (Rodeheffer et al., 2008;
Joe et al., 2009). Here, we investigated the possibility that phar-
macologic stimuli affect the behavior of adipose lineage and
adipose progenitors in adult mice. We found that rosiglitazone
(Rosi), a TZD class drug, stimulates both the differentiation and
the proliferation of the progenitors. Moreover, chronic TZD
administration results in a progenitor pool in which adipogenesis
and self-renewal are compromised.
RESULTS
TZDs Stimulate In Vivo Adipogenic Differentiation
An inherent feature of the AdipoTrak system is the ability to trace
the life cycle of the adipose lineage. In this inducible system,
the tet-transactivator (Dox-off) was recombined into the endog-
enous PPARg locus, a master gene in adipocyte biology (Tang
et al., 2008; Tontonoz and Spiegelman, 2008). We then
combined the PPARg-tTA allele with two complementary
reporter systems, TRE-H2B-GFP as well as TRE-Cre;R26RlacZ
(Soriano, 1999; Tumbar et al., 2004). The first arrangement,
‘‘PPARg-GFP,’’ drives expression of a nuclear-localized GFP
within the adipose lineage (Kanda et al., 1998; Hadjantonakis
and Papaioannou, 2004). H2B-GFP is thought stable in postmi-
totic cells (Schaniel and Moore, 2009); however, if the system
is suppressed by Dox, the GFP signal is diminished upon cell
death or proliferation and, in fat depots, when progenitors
leave the stromal-vascular (SV) compartment and differentiate
into mature buoyant adipocytes. The ‘‘PPARg-R26R’’ is a binary
(on or off) indelible marking system that is present in PPARg-
expressing cells and all descendants. The indelible marking is
achieved when Cre is driven in PPARg-expressing cells and,
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Figure 1. TZDs Stimulate New Adipocyte Formation
(A) Two-month-old AdipoTrak mice were treated with or without TZD while
receiving BrdU-water for 2 months, and adipocyte nuclei were probed for
BrdU uptake with flow cytometry. Top diagram is the experimental design. The
x axis of the flow profiles is GFP intensity, and the y axis is BrdU (bottom left
panels). The percent change of +TZD BrdU+GFP+ events compared to TZD
is displayed in the graph on the bottom right. n = 4 per cohort.
(B–E) Two-month-old AdipoTrak mice were treated as indicated for 2 months
and examined for reporter expression. IWAT and RWAT were stained (left
panels) or quantified (the graph on the right) for b-galactosidase activity (B). n =
4 per cohort. Adipocyte nuclei were analyzed for GFP with flow cytometry (C).
The relative percentages of GFP+ nuclei are graphed on the right. See also
Figure S1. n = 4–6 per cohort. IWAT and RWAT were stained (left panels)
or quantified (blue, the graph on the right) for b-galactosidase activity (D).
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TZDs Regulate Adipose Lineage Dynamicsby recombination, deletes the translational stop signal present
upstream of lacZ in the ROSA26 locus, allowing the permanent
expression of b-galactosidase, the level of which solely depends
on theROSA26 promoter. When integrated, these systems allow
assessment of adipose lineage dynamics.
TZDs are widely prescribed for Type II diabetes. In patients as
well as animal models, TZDs often increase fat mass and alter
fat morphology with the appearance of small adipocytes (Halla-
kou et al., 1997; Okuno et al., 1998; de Souza et al., 2001). To
investigate whether these changes might in part be secondary
to the recruitment of new adipocytes from a proliferating source,
we administered BrdU in the drinking water of AdipoTrak mice
and then randomized themice to either placebo or Rosi, a widely
prescribed TZD (Figure 1A). We then digested adipose depots
and separated the resultant cells with centrifugation into the
floated fraction containing buoyant adipocytes and the pelleted
stomal-vascular fraction (SVF) containing adipose stem cells
(Tang et al., 2008). We next evaluated the amount of BrdU incor-
porated into floated GFP+ adipocytes with flow cytometry. We
found that TZDs increased the amount of BrdU present in floated
AdipoTrak-marked adipocytes approximately 2-fold (Figure 1A).
We further explored the effects of TZDs on in vivo adipose
specification and formation of new adipocytes with the b-galac-
tosidase reporter system. To that end, we treated AdipoTrak
mice with a 2 month course of placebo or Rosi. We then deter-
mined the levels of adipose depot b-galactosidase and observed
a significant TZD-induced increase in X-gal staining and b-galac-
tosidase activity (Figure 1B). Since the R26R system is binary
(either on or off), these data indicate that TZDs induce the forma-
tion of a significant number of new cells.
We continued to probe the TZD-dependent effects on adipose
depots by administering Dox to suppress the AdipoTrak system.
We randomized AdipoTrak mice to receive a 2 month course of
either Dox alone or Dox with Rosi and then interrogated adipo-
cyte GFP levels with flow cytometry. We found that Rosi reduced
the percentage and fluorescent intensity of adipocytes that
expressed the GFP reporter in the presence of Dox (Figures 1C
and S1). These data support the notion of TZD-induced adipo-
cyte turnover and formation, thus paralleling the TZD-induced
increase in adipocyte BrdU incorporation and lacZ reporter
described above (Figures 1A and 1B).
To evaluate whether the newly formed adipocytes derived
from an AdipoTrak-marked source, we examined expression of
the permanent PPARg-R26R marker in the Dox-suppressed
state. Nonetheless, we again detected a roughly 1.5-fold in-
crease in b-galactosidase staining and activity even with Dox-
induced suppression (Figure 1D). We supplemented these
studies by replacing the R26RlacZ with an R26RRFP alleleAdipoTrak mice carrying an R26RRFP reporter were similarly treated, and total
RFP from all adipocytes isolated from each experimental group were quanti-
fied and displayed as a relative value in the graph on the right (red). Adipose
tissues were stained with X-gal, sectioned and counterstained with nuclear
fast red (top panels) (E). Black arrows point to small adipocytes rarely seen in
nontreated controls. Adipose tissues were examined for GFP, perilipin (lipid
droplets), and caveolin-1 (CAV1, cytoplasmic membrane) (bottom panels).
White arrows point to adipocytes that contain multiple lipid droplets rarely
seen in nontreated controls. *p < 0.05 by two-tailed Student’s t test. Error bars
indicate SEM. Scale bars: 2 mm in (B) left, (D) left; 50 mm in (E).
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Figure 2. TZDs Stimulate In Vivo Progenitor Proliferation and Differ-
entiation
(A and B) Adult AdipoTrak mice were treated as indicated for 2 months, and
adipose SV cells were analyzed for GFP (A) or the apoptotic marker Annexin V
(B) with flow cytometry. In (A), the x axis is GFP intensity; the y axis is PE
channel to illustrate the distribution of GFP+ cells. The percentage of GFP+
cells are as indicated at the top of the flow profiles and as displayed as percent
changes in the graph on the right. See also Figure S2. n = 4–6 per cohort. In
(B), the x axis is GFP intensity; the y axis is Annexin V. The relative percentages
of GFP+/Annexin V+ cells compared toTZD are shown on the right. n = 4 per
cohort.
(C) AdipoTrak mice were injected with BrdU for 5 consecutive days and then
treated with or without TZD for 1 month. Top diagram shows the experimental
design. Isolated SV cells (bottom left) and adipocyte nuclei (bottom right) were
analyzed for BrdU incorporation with flow cytometry. The relative percentages
of GFP+/BrdU+ cells are displayed at the bottom. n = 3–4 per cohort.
(D) Adipose tissues from mice treated as in (C) were sectioned and stained for
GFP, isolectin (red) and BrdU (blue). White arrows indicate label-retaining
progenitors located in the vascular niche. The percent of GFP+BrdU+ cells in
GFP+ cells on small (1–2 cells in diameter) or relatively larger (3–5 cells in
diameter) blood vessels (as stained positive for isolectin) were quantified and
displayed on the right. *p < 0.05 by two-tailed Student’s t test. Error bars
indicate SEM. Scale bars: 50 mm in (D) left.
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TZDs Regulate Adipose Lineage Dynamics(Madisen et al., 2010), and similar results were observed (Fig-
ure 1D). In the TZD-treated R26RlacZ and GFP reporter samples
(with or without Dox), histological analyses revealed clusters of
small intensely labeled cells, which could be nascent adipo-
cytes, as well as cells that contained multiple lipid droplets,
potentially due to adipocyte remodeling (Figure 1E).
TZDs Stimulate Progenitor Proliferation
To further investigate the possible source of the Rosi-induced
new adipocytes, we tracked the stem cell compartment com-
bining AdipoTrak marking, Rosi treatment, and Dox suppres-
sion. In concert with the observed changes in adipocytes, we
found that the number, percentage, and fluorescent intensity of
the SV progenitors were significantly reduced by Rosi (Figures
2A and S2). We next evaluated whether TZDs might alter the
rate of cell death in SV progenitors, which could account for
the observed GFP reduction. However TZDs did not significantly
change the apoptotic rate of the progenitors (Figure 2B). These
data support the notion that TZDs couple SV progenitor prolifer-
ation, adipogenic differentiation, and evolution of new adipo-
cytes. To examine such a potential flow from SV progenitors to
adipocytes, we prelabeled mice with BrdU, stopped BrdU,
and, during a 1 month chase, administered placebo or Rosi (Fig-
ure 2C). After this chase, we quantified BrdU levels in both the SV
and the adipocyte fractions and found that Rosi, compared to
placebo, induced a significant reduction in the progenitor BrdU
level accompanied by a commensurate increase in adipocyte
BrdU content (Figure 2C). We also found that the progenitors
that retained label, a hallmark of stem cells, after TZD treatment
were present in the vasculature (Figure 2D). Together, these data
indicate that TZDs stimulate SV-resident, AdipoTrak-marked
progenitors to divide and differentiate into new adipocytes.
TZDs Exhaust the Progenitor Pool
TZDs are a potent proliferative and adipogenic stimulus to
adipose progenitors in vivo (Figures 1 and 2). To assess the effect
of chronic TZD administration on the progenitor pool, we treated
AdipoTrak mice with a 2 month course of placebo or Rosi and
evaluated the SV fraction for GFP expression. These studies
were done in the absence of Dox, to eliminate the potential
confounds of suppressing the reporter system as described
above. Interestingly, we also observed a significant decrease in
the number and intensity of GFP+ progenitors present in the SV
fraction even in the nonsuppressed state (Figures 3A and S3).
Todeterminepossible functional consequencesof this reduction,
we again treatedmicewith placebo or Rosi for 2months, isolated
total SV as well as GFP+ cells (an equal number of GFP+ cells
wereplated fromplaceboandRosimice), andevaluated their adi-
pogenic potential in culture. Notably, in either case, chronic
in vivo TZD administration reduced in vitro adipogenesis based
upon oil red O staining and adipogenic marker quantification
(Figures 3B and 3C) (data not shown). This reduction contrasts
with the potent proadipogenic effect of in vitro TZD administra-
tion, such as that observed when Rosi was added to primary
cultures of SV or GFP+ sorted cells isolated from mice that did
not receiveRosi (Figure3D) (datanot shown).Onepossible expla-
nation for the reducedSVGFP expression observed after chronic
TZD exposure was that TZDs decreased the number of progeni-
tors present in the niche. However, the reduced adipogenic118 Cell Metabolism 14, 116–122, July 6, 2011 ª2011 Elsevier Inc.
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Figure 3. TZDs Exhaust the Progenitor Pool
(A–C) Adult AdipoTrakmicewere treatedwith or without TZD for 2months, and
the adipose SV cells were analyzed for GFP (A) or sorted for GFP+ cells, plated
in equal numbers, and cultured in insulin (B and C). In (A), the percentages of
GFP+ cells are as indicated at top of the flow profiles. The x axis is GFP
intensity; the y axis is APC channel to illustrate cell distribution. The relative
percentages of GFP+ cells, compared toTZD, are shown on the graph on the
right. See also Figure S3. n = 4 per cohort (B and C). Adipogenesis was
assayed with oil red O staining, (left two panels [B], fat stains red), triglyceride
quantification (graph on the right [B]), and qPCR analyses of a panel of adi-
pogenic markers (C). ADPN: adiponectin.
(D) SV cells from untreated AdipoTrak mice were isolated and cultured in
insulin with or without TZD. Adipogenesis was assayed by oil red O staining
(left two panels) and triglyceride quantification (right panel).
(E) AdipoTrak R26RlacZ or R26RRFP reporter mice were treated with or without
TZD for 2 months, and adipose SV cells were examined for b-galactosidase by
X-gal staining (left panels) and cell counting (2,500–5,500 cells, blue in the
graph) or RFP with flow cytometry (red in the graph). *p < 0.05 by two-tailed
Student’s t test. Error bars indicate SEM. Scale bars: 50 mm in (B), (D), and (E).
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TZDs Regulate Adipose Lineage Dynamicspotential of the GFP sorted cells indicates that this was not the
only perturbation. Another possibility was that the reduced GFP
levels resulted from altered behavior of the progenitor pool, forexample a division in which GFP is no longer expressed in
a subset of progeny. To distinguish between changes in progen-
itor number and changes in progenitor behavior, we turned to
lineage tracing methodology. To that end, we repeated the Adi-
poTrak chronic TZD studies, but in this case quantified the
number of SV cells that expressed the indelible lacZ or RFP
markers. Notably, and in contrast to the reduced stem cell GFP
expression (Figure 3A), TZDs had no effect on the number or
percentage of lineage-traced, b-galactosidase+ or RFP+, cells
present in the SV fraction (Figure 3E). These data support the
notion that chronic TZD administration depletes the adipogenic
capacity of the progenitor pool and induces a progenitor division
whereby some descendants display altered properties.
Chronic TZDs Alter the Molecular Signature of Adipose
Progenitors
We next began to probe the molecular underpinnings of the
changes induced in the progenitor pool by 2 months of TZD
administration. We interrogated AdipoTrak-labeled progenitors
derived from control or Rosi-treatedmicewith a panel of relevant
cell surface markers using flow cytometry. Although markers of
other lineages were unchanged, we found that chronic TZD
treatment significantly decreased the expression of several key
adipogenic stem cell markers (e.g., Sca1, CD29, CD24) as well
as mesenchymal stem cell markers (e.g., CD44) (Figure 4A)
(data not shown). These data further support the notion that
long-term TZD treatment alters the stem and progenitor pro-
perties of the AdipoTrak-labeled progenitor pool.
We also performed expression profiling, sorting and com-
paring the molecular signature of GFP+ progenitors isolated
from mice treated with or without TZD. We identified a battery
of genes whose expression was significantly different between
the two populations (Figure 4B); qPCR on selective genes vali-
dated the microarray data (Figures 4C and 4D). Many of the
genes downregulated by TZDs were secreted cytokines and
factors that regulate immune responses (e.g., TNF, CCLs, etc.).
TZDs have anti-inflammatory properties, and these data raise
the possibility that TZDs might exert such effects through
adipose progenitors, even though the progenitors do not belong
to the hematopoietic lineage (Tang et al., 2008). Notably, many of
the genes that were identified have previously established roles
in fat formation or obesogenic responses, and they were regu-
lated in a manner consistent with a potential role in the altered
adipogenic ability (Figure 4D). For example, levels of cathepsin
S (CTSS), a gene that promotes adipogenesis and is increased
in obesity and associated diseases (Taleb and Cle´ment, 2007),
were significantly reduced by TZDs. In contrast, genes such as
SPARC (secreted protein, acidic, cysteine-rich), an inhibitor of
adipogenesis and obesity (Kos and Wilding, 2010; Nagaraju
and Sharma, 2011), were increased by TZDs, as were TZD
targets such as RBP7 (retinol-binding protein 7) (Zizola et al.,
2008). We extended these studies by further examining the
potential role of one of the upregulated genes, p75NTR (p75
neurotrophin receptor), in progenitor adipogenesis. Because
chronic TZDs reduced adipogenesis, we hypothesized that
genes that were upregulated in this state might themselves be
adipogenic inhibitors. We selected p75, as it is a known stem
cell marker regulating differentiation in other lineages, and
because it is a cell surface marker thereby allowing directCell Metabolism 14, 116–122, July 6, 2011 ª2011 Elsevier Inc. 119
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Figure 4. In Vivo TZD Treatment Alters the Molecular Characteris-
tics of Adipose Progenitors
(A–D) Adult AdipoTrakmicewere treatedwith or without TZD for 2months, and
adipose GFP+ SV cells were analyzed with a panel of cell surface markers
(A) or sorted and interrogated with gene expression profiling (B) or qPCR
(C and D). In (A), somemarkers reduced by TZD are displayed as a percentage
of GFP+ cells that coexpressed the marker of interest. In (B), the heat map
illustrates 133 genes in which TZD induced differential expression. The color
bar on the right indicates gene expression level in log2 scale. n = 3–4 mice per
cohort, 3 cohorts for each experimental group. In (C) and (D), qPCR analyses of
selected genes identified from microarray that are involved in immune
response (C) or have established roles in fat formation or obesogenic
responses (D).
(E) GFP+ SV cells were stained with an anti-p75NTR antibody, and sorted into
p75 and p75+ fractions; equal numbers of cells from each fraction were
plated, incubated in insulin, and stained with oil red O. *p < 0.05 by two-tailed
Student’s t test. Error bars indicate SEM. Scale bars: 50 mm in (E).
Cell Metabolism
TZDs Regulate Adipose Lineage Dynamics
120 Cell Metabolism 14, 116–122, July 6, 2011 ª2011 Elsevier Inc.investigation of its function within the adipose lineage using cell
sorting. To that end, we compared the adipogenic potential of
AdipoTrak GFP+ cells further sorted into p75+ and p75
populations (Figure 4E). Consistent with the hypothesis, p75+
progenitors had significantly lower adipogenic potential than
progenitors that were p75 (Figure 4E). Taken together, these
studies provide initial molecular insights into how in vivo TZD
administration alters the adipogenic behavior and stem cell
properties of the AdipoTrak-marked progenitor pool.
DISCUSSION
Adipose depots regulate metabolism, and much interest stems
from the potential of altering adipose biology to therapeutic
ends; the vascular location of adipose progenitors indicates
that they might be therapeutically accessible (Tang et al., 2008;
Zeve et al., 2009). To explore this notion, we examined effects
of TZDs on adipose lineage and stem cell dynamics, as several
lines of evidence indicated a potential role (Hiragun et al., 1988;
Lehmann et al., 1995; de Souza et al., 2001; Tang et al., 2008;
Tontonoz and Spiegelman, 2008; Choi et al., 2010). Although
TZDs are effective at lowering blood glucose levels, side effects
and concerns that TZDs increase cardiovascular risk have
hastened the need to find alternative therapeutics (Nissen and
Wolski, 2007; Home et al., 2009). A better understanding of
whether and how TZDs modulate the adipose lineage may
shed light on their insulin-sensitizing efficacy, and may also
help to develop the next generation of insulin sensitizers.
Our studies indicate that TZDs enhance the homeostatic flow
of cells from the progenitor compartment to adipocytes. For
example, BrdU and AdipoTrak studies indicate that TZDs
roughly double the number of adipocytes formed during treat-
ment, compared to controls. A parallel stimulation was also
observed in the progenitor fraction, with marked changes in
the ephemeral AdipoTrak reporter supporting an evolution from
the progenitor compartment to differentiated cells. As an inde-
pendent measure of the notion that TZDs induce new adipocytes
to emanate from the progenitor fraction, we prelabeledmice with
BrdU and then quantified possible TZD-dependent changes in
BrdU levels in the stem and mature adipocyte compartments.
We found a significant reduction in BrdU in the progenitors and
a commensurate increase in adipocytes. Together the studies
indicate that TZDs activate the progenitors to proliferate, differ-
entiate, and form new adipocytes.
Notably, chronic TZD administration significantly altered the
progenitor pool, decreasing the number of GFP+ AdipoTrak-
marked cells present in the SV fraction and reducing the adipo-
genic potential of the total SV pool and of sorted GFP+ cells. One
possibility for these effects was that TZDs were such a potent
adipogenic stimulus that they induced progenitors to become
adipocytes without a commensurate replenishment of the stem
cell population. That is they uncoupled the normal homeostatic
balance of the progenitor pool. Lineage tracing with the indelible
reporter system indicated that the number of traced SV-resident
cells that derived from the progenitors was unchanged by TZDs.
This supports the notion that progenitor division appeared to be
coordinated with adipogenic exodus. Apparently, the progeny of
some of these divisions were different from those produced
during homeostasis; GFP expression and adipogenic capacity
Cell Metabolism
TZDs Regulate Adipose Lineage Dynamicswere reduced and cell surfacemarker and gene expression were
changed in a manner consistent with the observed phenotypic
changes. These data support potential TZD-induced divisions
in which daughter cells have lost some of the properties of the
mother cell. These observations open up potential new avenues
to manipulate adipocyte number and fat biology.
White adipose tissue plays a key role in regulatingmetabolism.
A thorough understanding of the physiology and pharmacolog-
ical responses of adipose tissue may help to develop strategies
for obesity and associated metabolic diseases. We found that
the TZD class of diabetes drugs alters the dynamics of adipo-
cytes and progenitors, which indicates that adipose progenitors
are therapeutically accessible. Further characterization of line-
age dynamics may provide additional means to regulate adipo-
cyte specification and turnover.
EXPERIMENTAL PROCEDURES
Animals
Mice were housed in a 12:12 light:dark cycle, and chow and water were
provided ad libitum. R26RRFP is available in the Jackson Laboratory (Stock
#007905). Doxycycline (0.5 mg/ml in 1% sucrose) was provided in the drinking
water and protected from light. BrdU was i.p. injected (100 mg/kg body mass)
or provided in the drinkingwater (0.5mg/ml in 1% sucrose) and protected from
light. Mice were fed with rosiglitazone at 0.0075% in normal chow (4% fat
mouse diet from Harlan TEKLAD) when desired. Rosi intake was estimated
to be 15 mg/kg body mass/day. All animals were maintained under the guide-
lines of the University of Texas Southwestern Medical Center Animal Care and
Use Committee, according to NIH guidelines.
SV and Adipocyte Fractionation
The fractionation of the SV cells and adipocytes was as described (Tang et al.,
2008), except that the SVF pellet was resuspended in erythrocyte lysis buffer
(0.83% NH4Cl in H2O) for 8 min to lyse red blood cells before being subjected
to flow cytometry or culture. Adipocyte nuclei were extracted as described
(Tang et al., 2008).
Flow Cytometry Analysis
Cell surface marker analysis and sorting of GFP+ and GFP cells were per-
formed on live cells stained with propidium iodide (PI) (1 mg/ml) or 7-AAD
(1 mg/ml) to exclude dead cells that incorporated dyes. Isolated and fixed
adipocyte nuclei were similarly stained and gated for dye positive nuclei events
to exclude nonnuclear debris. BrdU detection of SV cells was performed with
the APC BrdU Flow Cytometry Kit, according to the manufacturer’s instruc-
tions. Adipocyte nuclei were fixed in nuclei wash buffer (Tang et al., 2008),
containing 4% formaldehyde prior to the BrdU detection and spun at 3000 g.
Gene Expression Microarrays
Adipose GFP+ SV cells were sorted from six cohorts of adult AdipoTrak mice
(three or four mice per cohort), either treated with or without Rosi for 2 months.
These GFP+ SV cells were then subjected to gene expression microarrays
performed on the Illumina Mouse-6 V2 BeadChip arrays by the UTSWMC
Microarray Core as described (Tang et al., 2008). Genes considered to have
differential expression values between the TZD and +TZD groups showed
aR2-fold change in expression (at p < 0.05).
ACCESSION NUMBERS
The microarray data can be accessed through NCBI GEO database
(GSE30116).
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